ICD Co. Ltd (040910) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of ICD Co. Ltd KRW 12,322, price KRW 4,130, upside +198.4%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ICD Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 3,660 KRW – 15,593 KRW · fair‑value band 7,710 KRW – 24,674 KRW · the 4,130 KRW price screens below the 12,322 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow ICD Co. in your weekly email
Every Wednesday you see whether ICD Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ICD Co., Ltd. engages in the manufacture and sale of AMOLED, LCD, and semiconductor equipment in South Korea and internationally. The company offers DRY etcher and research-thermal evaporator. It also involves in bio and medical business by using plasma to develop devices and products for sterilization, medicine, cosmetics, etc.
Show more
ICD Co., Ltd. engages in the manufacture and sale of AMOLED, LCD, and semiconductor equipment in South Korea and internationally. The company offers DRY etcher and research-thermal evaporator. It also involves in bio and medical business by using plasma to develop devices and products for sterilization, medicine, cosmetics, etc. The company was founded in 2000 and is headquartered in Anseong-si, South Korea.
Stock analysis
ICD Co. Ltd (040910) currently trades at 4,130 KRW, while our model-based Fair Value estimate is 12,322 KRW, implying the stock looks roughly 66.5% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 10,369 KRW per share, and 10 of the 14 models we run sit above the 4,130 KRW price.
Bear case: the Earnings-Based group reads lowest at 1,905 KRW, and 4 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: 7,710 KRW (bear) to 24,674 KRW (bull), the price of 4,130 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Technology sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
ICD Co. Ltd reported revenue of 197B KRW in FY2025 versus 116B KRW in FY2021, a compound +14.2%/yr. Reported net income was −1.9B KRW in FY2025.
Key figures
Market cap 67.4B KRW (≈ $49.6M) · P/S ratio 0.32 · Net margin −1.0% · Return on equity 1.5% · Return on assets (EBIT) −7.5% · Operating margin −22.4% · Revenue (TTM) 202B KRW · Revenue growth (YoY) +28.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −66% fair-value upside, at 198%, 040910 screens cheaper than that median.
Fair Value models
Bear 7,710 KRWFair Value 12,322 KRWBull 24,674 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+33.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.6%
Start year 2020 (pandemic)
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
’13
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.2% (2020) → 2.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −8.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Electronic Components · 654 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside+198% · Top 25%
Profitability
Return on equity (TTM)2% · Below median
Return on assets2% · Below median
Net margin (TTM)1% · Below median
Operating margin (TTM)−22% · Bottom 25%
Growth and dividend
Revenue growth29% · Top 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Electronic Components median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ICD Co. Ltd (040910) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 12,322 KRW versus a price of 4,130 KRW, about +198% upside (undervalued).
What is the fair value of 040910?
Our model-based fair value for ICD Co. Ltd is 12,322 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 4,130 KRW.
What is the quality score of 040910?
ICD Co. Ltd has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ICD Co. Ltd (040910)?
Our model-based price target is the fair value of 12,322 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 7,710 KRW, optimistic scenario 24,674 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ICD Co. Ltd stock forecast for 2026?
Our models put fair value at 12,322 KRW, about +198% upside versus a price of 4,130 KRW (undervalued). Cautious scenario 7,710 KRW, optimistic scenario 24,674 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ICD Co. Ltd (040910)?
ICD Co. Ltd reported trailing-twelve-month revenue of about 202B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into ICD Co. Ltd (040910)?
For today's price to be fair in a discounted-cash-flow model, ICD Co. Ltd would have to grow free cash flow by -6.6 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -8.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 040910 use?
Our models discount ICD Co. Ltd at 9.5 %: a base by market capitalisation (nano), damped by beta 0.76, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ICD Co. Ltd that is -6.6 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has ICD Co. Ltd (040910) delivered so far?
Over the past 5 years revenue at ICD Co. Ltd grew -8.6 % a year. The price currently implies -6.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ICD Co. Ltd (040910) growing?
The median revenue growth in the sector is +8.2 % a year. That is the yardstick for the growth priced into ICD Co. Ltd (-6.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ICD Co. Ltd (040910)?
The free-cash-flow yield on the price is 10.58 %: that much free cash flow ICD Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ICD Co. Ltd (040910)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ICD Co. Ltd it is 12,322 KRW per share (as of Sep 24, 2026), against a price of 4,130 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is ICD Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 040910 trades below its calculated fair value: price 4,130 KRW, fair value 12,322 KRW, a gap of about +198% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 040910?
No. The price is what the market pays today (4,130 KRW); the fair value is what the company's own numbers justify (12,322 KRW). For ICD Co. Ltd the two are 8,192 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ICD Co. Ltd worth?
The market values ICD Co. Ltd at about 67.4B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 4,130 KRW; our models calculate a fair value of 12,322 KRW per share.
What do the bullish and bearish scenarios say about 040910?
Our models span a range for ICD Co. Ltd: cautious scenario 7,710 KRW, base 12,322 KRW, optimistic 24,674 KRW per share (as of Sep 24, 2026, price 4,130 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ICD Co. Ltd (040910)?
Balance-sheet figures for ICD Co. Ltd (as of Sep 24, 2026): return on equity 1.5%, debt of 0.01 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 040910 from its 52-week high?
ICD Co. Ltd trades at 4,130 KRW, about 36% below its 52-week high of 6,470 KRW and 12% above the low of 3,680 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 12,322 KRW is for.
Which stocks are comparable to ICD Co. Ltd?
From the same area (Technology) we also value Amphenol Corporation, Delta Electronics, Inc, Corning Incorporated, Hon Hai Precision Industry Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ICD Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 4,130 KRW, calculated fair value 12,322 KRW (+198%), Quality Score 67/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 040910 calculated?
We run ICD Co. Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 12,322 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. ICD Co. Ltd currently trades 198 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ICD Co. Ltd (040910)?
The closing price on Sep 23, 2026 was 4,130 KRW. Our model-based fair value is 12,322 KRW, about +198% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ICD Co. Ltd right now?
The price is below even our cautious bear case (7,710 KRW). The market is more pessimistic than our downside scenario. The model range is unusually wide (7,710 KRW to 24,674 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of ICD Co. Ltd
How large is the market capitalisation of ICD Co. Ltd (040910)?
The market capitalisation of ICD Co. Ltd is 67.4B KRW (≈ $49.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ICD Co. Ltd (040910)?
The price-to-sales ratio of ICD Co. Ltd is 0.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ICD Co. Ltd (040910)?
The net margin of ICD Co. Ltd is −1.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ICD Co. Ltd (040910)?
The return on equity (ROE) of ICD Co. Ltd is 1.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ICD Co. Ltd (040910)?
On an EBIT basis the return on assets of ICD Co. Ltd is −7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ICD Co. Ltd (040910)?
The operating margin of ICD Co. Ltd is −22.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ICD Co. Ltd (040910)?
Revenue at ICD Co. Ltd is growing +28.6% versus a year earlier (3y avg +9.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ICD Co. Ltd (040910)?
Earnings per share at ICD Co. Ltd are growing +478% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does ICD Co. Ltd (040910) carry?
The net debt of ICD Co. Ltd is 9.6B KRW (fiscal year 2025, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ICD Co. Ltd in the live analysis
One click puts ICD Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
